Elizabeth Bebin
Neurology with Special Qualifications in Child Neurology · Birmingham, ALNPI 1437236882
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,450 of the $15,293 with a category attached, or 68.3%. 8 manufacturers reported payments, led by Greenwich Biosciences, Inc. at 35.4% of the total. Reporting peaked in 2019 at $8,166 and has fallen 98.1% since, to $159 in 2023.
Across 24 payments — averaging $637.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$5K
- Biocodex, Inc.$4K
- Neurelis, Inc.$3K
- Jazz Pharmaceuticals Inc.$2K
- Aquestive Therapeutics, Inc.$1K
- Livanova USA, Inc.$85
- plus $29 from 2 others
Across 24 payments — averaging $154,722 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lundbeck LLC$3.5M
- Jazz Pharmaceuticals Inc.$112K
- GW Research Limited$80K
- Novartis$18K
What the payments were for
- Consulting fees$10,45068%
- Speaking & faculty fees$3,10020%
- Travel & lodging$1,0707%
- Food & beverage$6694%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 8 | $5,412 |
| Biocodex, Inc. | 6 | $3,803 |
| Neurelis, Inc. | 3 | $3,085 |
| Jazz Pharmaceuticals Inc. | 3 | $1,858 |
| Aquestive Therapeutics, Inc. | 1 | $1,020 |
| Livanova USA, Inc. | 1 | $85 |
| Immedica Pharma US, Inc. | 1 | $15 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,293 in reported general payments places this provider in the 80th percentile of 24 neurology with special qualifications in child neurology providers in Alabama.
See all neurology with special qualifications in child neurology providers in Alabama →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vigabatrin | 12 | $234,998 |
| AfinitorEverolimus | 12 | $209,438 |
| EpidiolexCannabidiol (Cbd) | 16 | $69,135 |
| Everolimus | 13 | $60,175 |
| Sirolimus | 13 | $15,492 |
| FycompaPerampanel | 11 | $13,596 |
| Divalproex Sodium | 20 | $4,017 |
| Carbamazepine | 11 | $1,018 |
| Lamotrigine | 24 | $486 |
| Escitalopram Oxalate | 14 | $281 |
| Clobazam | 13 | $105 |
| Clonazepam | 30 | $88 |
| Quetiapine Fumarate | 14 | $64 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Birmingham
- Alyssa ReddyBirmingham$68K
- Alan PercyBirmingham$51K
- Michael LopezBirmingham$22K
- Amitha AnanthBirmingham$10K
- Jan MathisenBirmingham$8K
- Monisha GoyalBirmingham$8K
- Kathryn LalorBirmingham$3K
- Pongkiat KankirawatanaBirmingham$2K
- Emily GantzBirmingham$1K
- Katherine ThaggardBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.